The metformin group had a lower risk of primary cesarean section (aOR, 0.57; 95% CI, 0.40–0.82; p = 0.002) and congenital malformations (aOR, 0.51; 95% CI, 0.27–0.94; p = 0.032) compared with the insulin group. This evidence concerns the gene INS and pregnancy disorder.